PTC Therapeutics, Inc. (ETR:BH3)

Market Cap	4.99B +50.0%
Revenue (ttm)	882.96M -42.8%
Net Income	-33.60M
EPS	-0.41
Shares Out	n/a
PE Ratio	n/a
Forward PE	47.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28
Open	60.74
Previous Close	61.56
Day's Range	60.74 - 60.74
52-Week Range	59.76 - 78.18
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children....

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 991
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: BH3

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 24, 2026

Data Sources Report a data error